Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRMakoto Maemondo, Toshihiro Nukiwa, Akira Inoue et al.|New England Journal of Medicine|2010Cited by 5.6k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Tatsuro Fukuhara et al.|The Lancet Oncology|2019Cited by 636
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 StudyYukio Hosomi, Satoshi Morita, Shunichi Sugawara et al.|Journal of Clinical Oncology|2019Cited by 483
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03Satoshi Teramukai, Masanori Fukushima, Tadashi Mio et al.|European Journal of Cancer|2009Cited by 342